# All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

> **NCT05345002** · PHASE2 · RECRUITING · sponsor: **Stephen Bagley, MD, MSCE** · enrollment: 55 (estimated)

## Conditions studied

- Glioma
- IDH Mutation
- Astrocytoma
- Oligodendroglioma

## Interventions

- **DRUG:** Retifanlimab
- **DRUG:** All-trans retinoic acid

## Key facts

- **NCT ID:** NCT05345002
- **Lead sponsor:** Stephen Bagley, MD, MSCE
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-16
- **Primary completion:** 2027-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05345002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05345002, "All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05345002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*